Muscular Dystrophy – Epidemiology – Mature Markets

Clarivate Epidemiology’s coverage of muscular dystrophy comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of muscular dystrophy for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.

Clarivate Epidemiology’s muscular dystrophy forecast will answer the following question:

  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of muscular dystrophy over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology provides at least 10 years of forecast data for the following muscular dystrophy patient populations:

  • Diagnosed incidence of Duchenne muscular dystrophy (DMD).
  • Diagnosed prevalence of Becker muscular dystrophy.
  • Diagnosed prevalence of congenital muscular dystrophy.
  • Diagnosed prevalence of distal muscular dystrophy.
  • Diagnosed prevalence of DMD.
  • Diagnosed prevalence of Emery-Dreifuss muscular dystrophy.
  • Diagnosed prevalence of facioscapulohumeral muscular dystrophy.
  • Diagnosed prevalence of limb-girdle muscular dystrophy.
  • Diagnosed prevalence of myotonic dystrophy.
  • Diagnosed prevalence of oculopharyngeal muscular dystrophy.
  • Diagnosed prevalence of DMD by ambulation.
  • Diagnosed prevalence of DMD amenable to exon-skipping therapy.
  • Diagnosed prevalence of DMD by nonsense mutations.

Note: Coverage may vary by country and region.

launch Related Market Assessment Reports